In short, offers a dual‑action profile: anti‑craving + anti‑depressive/anti‑anxiolytic , a therapeutic niche not covered by current FDA‑approved medications for AUD (naltrexone, acamprosate, disulfiram).
If you want, I can:
Pre‑clinical electrophysiology (slice recordings) shows that a single 30 mg dose reduces NOP‑mediated IPSCs by ~85 % in the central amygdala, with no measurable effect on MOR‑mediated currents.
Рассчитайте стоимость поездки заранее, заполнив онлайн форму на сайте
In short, offers a dual‑action profile: anti‑craving + anti‑depressive/anti‑anxiolytic , a therapeutic niche not covered by current FDA‑approved medications for AUD (naltrexone, acamprosate, disulfiram).
If you want, I can:
Pre‑clinical electrophysiology (slice recordings) shows that a single 30 mg dose reduces NOP‑mediated IPSCs by ~85 % in the central amygdala, with no measurable effect on MOR‑mediated currents.
